CNBC |
Novo Nordisk's oral diabetes drug beats Jardiance in study
CNBC The success of oral semaglutide in the Phase III trial is a boost for a medicine seen as important for ensuring the group's long-term growth in a highly competitive diabetes market. The once-daily pill, which Novo hopes to launch in 2020, belongs to a ... |
from diabetes - Google News
Social Plugin